PC-US-122693_US_JARDIANCE_Jardiance_A1C_banner_based_on_PC-US-114455_728x90

T2D requires many
treatment
considerations^1,2

When addressing hyperglycemia,
body weight and systolic blood
pressure may also need to be
considered*

*JARDIANCE is not indicated for weight loss or
blood pressure reduction.³

For adults with type 2 diabetes, along with diet and exercise

When added to metformin,
JARDIANCE significantly
reduced A1C

A1C REDUCTION FROM BASELINE⁴
AT 24 WEEKS

Mean change
from baseline
(7.9%), (n=213)

Adjusted mean changes of -0.1% from a baseline of
7.9% for placebo (n=207), -0.7% from a baseline of
7.9% for JARDIANCE 10 mg (n=217), and -0.8% for
JARDIANCE 25 mg (n=213), respectively. Difference
from placebo + metformin (adjusted mean) was
-0.6% for both JARDIANCE 10 mg and 25 mg; p<0.0001
vs placebo.

Scroll to the right for the EMPA-REG Outcome Trial Design^†

For adults with type 2 diabetes, along with diet and exercise

Patients experienced additional
benefits, such as weight loss*

WEIGHT REDUCTION FROM BASELINE⁴
AT 24 WEEKS

Mean change from baseline
(BMI 29.7, 181 Ib), (n=213)

Adjusted mean changes of -0.5% reduction in
body weight (-0.9 Ib) from a baseline of 176 Ib
for placebo (n=207), -2.5% (-4.5 Ib) from a
baseline of 180 Ib for JARDIANCE 10 mg
(n=217), and -2.9% (-5.2 Ib) from a baseline of
181 Ib for JARDIANCE 25 mg, respectively;
p<0.0001 vs placebo.

*JARDIANCE is not indicated for weight loss or blood
pressure reduction. weight loss and SBP reduction
were secondary endpoints.³

For adults with type 2 diabetes, along with diet and exercise

And additionally, lower SBP*

SYSTOLIC BLOOD PRESSURE
REDUCTION FROM BASELINE⁵

Systolic Blood Pressure
was reduced by

Placebo-corrected mean changes of
-4.1 mmHg from a baseline of 129.6 mmHg for
JARDIANCE 10 mg and -4.8 mmHg from a
baseline of 130.0 mmHg for JARDIANCE 25 mg;
JARDIANCE vs placebo p<0.0001 for both
doses.

*JARDIANCE is not indicated for weight loss or blood
pressure reduction. Weight loss and SBP reduction
were secondary endpoints.³

from a baseline of 130 mmHg
at week 24

Learn more about what
JARDIANCE can do for
your patients

VIEW CLINICAL DATA >

Not for type 1 diabetes, or for type 2 diabetes
with an eGFR <30 mL/min/1.73m².

Prescribing Information and Medication Guide

IMPORTANT SAFETY INFORMATION AND INDICATIONS

CONTRAINDICATIONS: Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE, reactions such as angioedema have occurred; patients on dialysis.

WARNINGS AND PRECAUTIONS

Ketoacidosis: Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been identified in patients with type 1 and type 2 diabetes mellitus receiving SGLT2 inhibitors, including empagliflozin. Fatal cases of ketoacidosis have been reported in patients taking empagliflozin. Patients who present with signs and symptoms of metabolic acidosis should be assessed for ketoacidosis, even if blood glucose levels are less than 250 mg/dL. If suspected, discontinue JARDIANCE, evaluate, and treat promptly. Before initiating JARDIANCE, consider risk factors for ketoacidosis. Patients may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis. For patients who undergo scheduled surgery, consider temporarily discontinuing JARDIANCE for at least 3 days prior to surgery.

Volume Depletion: Empagliflozin can cause intravascular volume depletion which may manifest as symptomatic hypotension or acute transient changes in creatinine. Acute kidney injury requiring hospitalization and dialysis has been reported in patients with type 2 diabetes receiving SGLT2 inhibitors, including empagliflozin. Before initiating, assess volume status and renal function in patients with impaired renal function (eGFR <60 mL/min/1.73 m²), elderly patients or patients on loop diuretics. In patients with volume depletion, correct this condition. After initiating, monitor for signs and symptoms of volume depletion and renal function.

Urosepsis and Pyelonephritis: Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have been identified in patients receiving SGLT2 inhibitors, including empagliflozin. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate for signs and symptoms of urinary tract infections and treat promptly.

Hypoglycemia: The use of JARDIANCE in combination with insulin or insulin secretagogues can increase the risk of hypoglycemia. A lower dose of insulin or the insulin secretagogue may be required.

Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Serious, life-threatening cases requiring urgent surgical intervention have occurred in both females and males. Serious outcomes have included hospitalization, multiple surgeries, and death. Assess patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise. If suspected, institute prompt treatment and discontinue JARDIANCE.

Genital Mycotic Infections: Empagliflozin increases the risk for genital mycotic infections, especially in patients with prior infections. Monitor and treat as appropriate.

Hypersensitivity Reactions: Serious hypersensitivity reactions have occurred with JARDIANCE (angioedema). If hypersensitivity reactions occur, discontinue JARDIANCE, treat promptly, and monitor until signs and symptoms resolve.

MOST COMMON ADVERSE REACTIONS (≥5%): Urinary tract infections and female genital mycotic infections.

DRUG INTERACTIONS: Coadministration with diuretics may enhance the potential for volume depletion. Monitor for signs and symptoms.

USE IN SPECIAL POPULATIONS

Pregnancy: JARDIANCE is not recommended during the second and third trimesters.

Lactation: JARDIANCE is not recommended while breastfeeding.

Geriatric Use: JARDIANCE is expected to have diminished efficacy in elderly patients with renal impairment. Renal function should be assessed more frequently in elderly patients. The incidence of volume depletion-related adverse reactions and urinary tract infections increased in patients ≥75 years treated with empagliflozin.

INDICATIONS AND LIMITATIONS OF USE

JARDIANCE is indicated:

to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure and reduced ejection fraction.
to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

JARDIANCE is not recommended in patients with type 1 diabetes mellitus. It may increase their risk of diabetic ketoacidosis.

JARDIANCE is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR <30 mL/min/1.73 m². JARDIANCE is likely to be ineffective in this setting based upon its mechanism of action.

CL‑JAR‑100092 08.18.2021

Please see JARDIANCE Prescribing Information and Medication Guide.

^†Add-on to metformin: A Phase III, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of JARDIANCE (10 mg, 25 mg) administered orally once daily over 24 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control despite treatment with metformin ≥1500 mg alone. Six hundred thirty-seven treated patients received placebo + metformin (N=207), JARDIANCE 10 mg + metformin (N=217), or JARDIANCE 25 mg + metformin (N=213). The primary endpoint was A1C change from baseline. Weight change and blood pressure change from baseline were secondary endpoints.¹

T2D=Type 2 Diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the Jardiance^® trademark under license. The other trademarks referenced above are owned by third parties not affiliated with Boehringer Ingelheim Pharmaceuticals, Inc.

References: 1. American Diabetes Association. Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42 (Suppl 1):S1-S193. 2. Das SR, Everett BM, Birtcher KK, et al. J Am Coll Cardiol. 2018;72(24):3200-3223. 3. Roden M, Weng J, Eilbracht J, et al; EMPA-REG MONO Trial Investigators. Lancet Diabetes Endocrinol. 2013;1(3):208-219. 4. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc. 5. Häring HU, Merker L, Seewaldt-Becker E, et al; EMPA-REG MET Trial Investigators. Diabetes Care. 2014;37(6):1650-1659.